Tetraspanin CD151, also known as PETA-3 or SFA-1, has been reported to predict prognosis in various solid tumors. Yet, the results of these studies remained inconclusive. Here, we performed this meta-analysis of relevant studies published on the topic to quantitatively evaluate the clinicopathological significance of CD151 in solid tumors. The relevant articles were identified via searching the PubMed, Web of Science and Embase database. The pooled hazard ratios (HRs) and corresponding 95% confidence intervals (CI) of overall survival (OS) and disease-free survival (DFS) were calculated to evaluate the prognostic value of CD151 expression in patients with solid tumors. A total of 19 studies involving 4, 270 participants were included in the study, we drew the conclusion that CD151 overexpression was associated with statistically significant poor OS (pooled HR = 1.498, 95% CI = 1.346-1.667, P<0.001) and poor DFS (pooled HR = 1.488, 95% CI = 1.314-1.685, P<0.001). Furthermore, the subgroup analysis revealed that the associations between CD151 overexpression and the outcome endpoints (OS or TTP) were significant within the Asian region and European, as well in patients with breast cancer or gastric cancer. Taken together, the incorporative HR showed CD151 overexpression was associated with poor survival in human solid tumors. CD151 could be a valuable prognosis biomarker or a potential therapeutic target of solid tumors.
INTRODUCTION
Tetraspanins CD151, a known transmembrane 4 superfamily protein, contains several different structure domains. Expression of CD151 was observed in different cell types [1] . CD151 and other tetraspanins participate in a variety of key cellular functions [1] [2] [3] . CD151 is the first characterized member of the tetraspanin family. It is also known as glycoprotein-27 (GP-27), Red blood cell antigen MER 2 (MER 2), platelet-endothelial tetraspan antigen-3 (PETA-3), Raph blood group antigen (RAPH)/Membrane Glycoprotein SFA-1 (SFA-1) and tetraspanin-24 (TSPAN-24), was located on chromosome 11p15.5 [4, 5] . Its expression was found in a number of cell types [6] . Altered expression of CD151 was involved in cancer growth [7] , progression [8] , motility, invasion, and metastasis [9] . Existing evidences have demonstrated that CD151 overexpression was observed in several malignancies [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . These striking evidences on the role of CD151 in cancer suggest the tetraspanin would Review be further considered as a novel potential oncotarget of cancer patients.
An increasing number of studies showed that increased CD151 expression in tumor tissue was associated with cancer patients' poor survival [10-13, 15, 17-27] . However, in invasive lobular breast cancer [15] and endometrial cancer [16] , overexpression of CD151 might have diverse, even opposing roles, correlating with better clinical outcomes. The results of those individual studies were inconsistent. Thus, this comprehensive metaanalysis was performed to clarify the possible prognostic role of CD151 expression in solid tumors.
RESULTS

Demographic characteristics
125 articles were retrieved from the different databases (PubMed, Embase, and Web of Science). As showed in the search flow diagram (Figure 1 ), 125 records were initially retrieved through the pre-defined search strategy. Because of repeated data, 65 records were removed. After browsing the retrieved titles and abstracts, 39 records were excluded due to no relevant endpoint provided. The remaining 26 records were downloaded as full-text and accessed very carefully. Among them, another 18 studies were excluded, including 1 study that was experimental study, 7 studies that were without prognosis data. After selection, 18 published studies including 4, 270 patients were finally selected for this meta-analysis. The median sample-size was 145, with a wide range from 30 to 886. Among all cohorts, Asian (n = 14) became the major source region of literatures, followed by Austria (n = 1), Poland (n = 2), USA(n = 1), UK (n = 1). NewcastleOttawa Scale (NOS) were applied to analyze these studies. The quality scores of these studies ranged from 6 to 9, indicating that the methodological quality was high.
As for the cancer type, two studies evaluated non-small cell lung cancer; Two studies focused on glioblastoma; Three studies evaluated breast cancer; One study evaluated gallbladder carcinoma; Three studies evaluated gastric carcinomas; One study evaluated CCRCC or clear cell renal cell carcinoma; One study evaluated esophageal squamous cell carcinoma; One study evaluated pancreatic cancer; Two studies evaluated liver cancer; One study evaluated prostate cancer; One study evaluated colon cancer, and one study evaluated endometrial cancer. Of all the studies, 19 of them focused on OS, other 10 studies focused on DFS. 
Analysis of possible publication bias and sensitivity analysis
In this study, we utilized the Begg's funnel plot as well as the Egger's test to evaluate the possible publication bias. As demonstrated, the funnel plots shapes for the OS and DFS had no obvious heterogeneity (Figure 4) , and Egger's tests revealed only slight publication bias concerning OS (P=0.097), but not DFS (P=0.839). Therefore, we performed trim and fill method to make pooled HR more reliable, and the pooled HR P value was also less than 0.01 (Figure not shown) . Next, we performed the sensitivity analysis to determine the robustness of the above results. Not a single study was identified to dominate the current meta-analysis, and deletion of each single study had no significant impact on the general conclusions ( Figure 5 ).
DISCUSSION
Tetraspanin CD151 is composed of various structure domains [4] . Site-directed mutagenesis studies have revealed that CD151 could be palmitoylated at multiple sites, which is vital for the assemble of tumor endothelial marker (TEM) network [28, 29] . For instance, CD151 interacts with α3β1 and α6β4 integrins via intracellular N-terminal and C-terminal cysteine palmitoylation [28] . Studies have demonstrated that integrin subunits α3 and α6 may directly associate with CD151 at QRD194-196 site [30] .
As the first identified member of the tetraspanin family, CD151 was shown to participate in tumor cell behaviors, including cell growth, proliferation, motility and invasiveness, possibly via interacting with a number of different proteins. CD151 silence could decrease above cancer cell behaviors [31] [32] [33] [34] [35] [36] . Existing evidences have also shown that CD151 expression is also important for tumor neoangiogenesis and epithelial-tomesenchymal transition [35, 37] .
In addition, clinical studies had investigated the potential prognostic value of CD151. Most of these studies, however, include only limited number of patients, and the results are inconclusive. CD151 overexpression often predicts unfavorable outcome in many cancer, such as gastric [11, 14, 24] , prostate [10] and non-small cell lung cancer [18, 27] . On the other hand, it is a favorable prognostic indicator in invasive lobular breast cancer [15] and endometrial cancer [16] . To our knowledge, the present study is the first and most full-scale meta-analysis systemically exploring the possible prognostic role of CD151 up-regulation in solid malignancies.
We that an undesirable impact of CD151 redundancy was correlated with not only the overall survival, but also disease-free survival. Additionally, Several important implications in this meta-analysis were displayed. High CD151 expression is very likely a general cancer's poor prognostic marker. We included a total of twelve different cancer types [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . The pooled results showed that high CD151 expression was associated with patients' poor OS and DFS. These conclusion could possibly be extended to all the solid tumors. Finally, it foreshadow the potential of CD151 developing a valuable therapeutic target and prognostic biomarker for solid tumor.
In conclusion, the significant association between CD151 over-expression and cancer patients' poor survival was clearly demonstrated in the present meta-analysis. These results indicate that CD151 could be a potential prognostic biomarker and a promising therapeutic oncotarget for solid tumors.
MATERIALS AND METHODS
Publication search
This present meta-analysis was performed with the guidelines from Preferred Reporting Items for Systematics Reviews and Meta-Analyses [38] . Databases including PubMed, EMBASE and Web of Science were searched from their incipiency to June, 2016 using the search terms: 'CD151', 'Tetraspanin' and 'cancer or tumor or neoplasm or carcinoma' and 'prognosis or prognostic or survival or predict or outcome or alive' and the following limits: Human, article in English. All potentially eligible studies were retrieved. The bibliographies in these studies were also carefully scanned to identify other possible eligible studies and extra studies. At a situation when multiple studies of the same patient population were identified, the published report with the largest sample size was included.
Inclusion criteria
To be eligible for selection of this meta-analysis, studies: (a) should test CD151 expression for prognostic value in cancer; (b) CD151 expression was tested by immunohistochemistry (IHC) or quantitative real-time polymerase chain reaction (qRT-PCR); (c) should have hazard ratios (HRs) with 95% confidence intervals (CIs), or should enable calculation of these statistics from the data presented; (d) should classify CD151 expression as "high" and "low" or "positive" and "negative"; (e) should be written in English.
Exclusion criteria
Exclusion criteria were: (a) literatures such as letters, editorials, abstracts, reviews, case reports and expert opinions were excluded; (b) experiments were performed in vitro or in vivo, but were not associated with patients; (c) articles showing on HRs with 95% CI of OS, or the Kaplan-Meier curves which had inadequate survival data for further analysis; (d) The duration of the follow-up study was less than three years.
Data extraction
Two outcome endpoints were analyzed: overall survival (OS) and disease-free survival (DFS). Parameters of these literatures were extracted from each single paper, including the first author's surname, publication year, country origin, number of total patients, antibodies utilized, types of measurements, score for CD151 assessment, CD151's cut-off values, as well as OS and DFS. The main features of these selected studies were summarized in Table 1 .
Cancer-specific survival, disease-specific survival and five-year OS were combined into OS. On the other hand, cumulative recurrence and progression-free survival were combined into DFS. OS was expressed as time (in months) from cancer diagnosis to death. To assess prognostic value of CD151 expression, multivariate hazard ratio (HR) was extracted. For the articles in which prognosis was plotted only as the Kaplan-Meier curves, the Engauge Digitizer V4.1 was then applied to extract survival data, and the Tierney's was utilized to calculate the HRs and 95% CIs [39] .
Statistical analysis
Pooled HRs and 95% CIs for two outcome endpoints (OS and DFS) were calculated. Statistical heterogeneity was assessed through the Chisquare test and I-square test, which was checked through the Q test, and a P value >0.10 indicated a lack of heterogeneity. We also quantified the effect of heterogeneity via I 2 =100%×(Q -df)/Q. I 2 values of <25% could be considered "low", values of about 50% could be considered "moderate", and values of over 75% could be considered "high" [40] . According to the absence or presence of heterogeneity, randomeffects model or fixed-effects model was applied to merge the RR, respectively. Without statistical heterogeneity, a fixed-effects model was employed to calculate the pooled HRs, otherwise the random-effects model was performed [41] . Funnel plots and the Egger's test were utilized to determine the possible publication bias [26] . Sensitivity analysis was also tested. Statistical analyses were performed via the Stata 14.0 (StataCorp, College Station, TX). P values for all comparisons were two-tailed.
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